Physician profile
Lance Reynolds
NPI 1215989876
$1,057.94
in general payments reported to CMS, 2019-2025
15 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.18 · 2021: $33.83 · 2022: $277 · 2023: $365 · 2024: $199 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.78 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $149.04 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $136.09 | 2019-2025 | Eliquis, Camzyos |
| Abbvie INC. | $131.85 | 2022-2023 | |
| Lundbeck LLC | $111.54 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $107.22 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $86.40 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $63.78 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $53.09 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $50.55 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $40.95 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $40.21 | 2022 | |
| Novo Nordisk INC | $38.78 | 2022-2024 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $16.30 | 2021 | |
| Sumitomo Pharma America, INC. | $16.25 | 2024 | Gemtesa |
| Exact Sciences Corporation | $15.89 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.